FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending January 2010

 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 
Notification of Transactions of Directors, Persons Discharging 
Managerial Responsibility or Connected Persons


The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and 
the under-mentioned
 person
s
 on 12 January 2010
 of an increase in their notional interests 
in Ordinary 
shares at a price of £12.94
 per share and Ordinary
 Share ADRs at a price of $41.48
 per ADR
 
following the notional re-investment of the dividend paid to shareholders on 
7 January 2010
.



Ordinary 
shares
ADRs
Mr A 
P 
Witty
10,198.95

Mr J 
S 
Heslop
4,
995.50

Dr M 
M 
Slaoui

2,
618.17
Mrs C E Bruck Slaoui

7
2.54
Mr S M Bicknell
4
75.57

Mr J
 M
 Clarke
2,
865.76

M
rs
 D P
 Connelly

920.23
Mr M Dunoyer
1,
202.46

Mr E J Gray
1,3
63.65

Mr S A Hussain
1,4
56.88

Mr D Learmouth
7
90.88

Mr W C Louv

9
48.61
Mr D 
J 
Phelan

1,460.86
 
Dr D Pulman

1,
109.95
Mr D S Redfern
6
40.89

Mr J R Stéphenne 
1,2
64.42

Ms C Thomas
689.60

Mr D E Troy

1,
399.2
4


The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to 
transaction
s
 notified in accordance with
 Disclosure and Transparency R
ule
s 3.1.4R(1)(a).
 


V A Whyte
Deputy 
Company Secretary

13 January 2010

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: January 13, 2010

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc